A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia (NCT06079398)
A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial, Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Infants (0 to <2 Years of Age) With Achondroplasia Followed by an Open Label Extension (OLE) Period
๐ฉบ Plain-English Summary (8th-Grade Level)
This trial is a Phase 2, multicenter, double-blind, randomized (ratio 2:1 TransCon CNP vs. placebo), placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 ฮผg CNP/kg of Navepegritide (TransCon CNP) administered SC once-weekly for 52 weeks in infants with genetically verified heterozygous ACH, aged 0 to \< 2 years at the time of randomization.
Who can join: Review the eligibility criteria below.
Location: Ascendis Investigational Site โ Saint Paul, Minnesota
Age range: 0 Years to 2 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (18 Sites)
- Ascendis Investigational Site โ Saint Paul, Minnesota
- Ascendis Investigational Site โ Houston, Texas
- Ascendis Investigational Site โ Madison, Wisconsin
- Ascendis Investigational Site โ Parkville,
- Ascendis Investigational Site โ Linz,
- Ascendis Investigational Site โ Montreal,
- Ascendis Investigational Site โ Copenhagen,
- Ascendis Investigational Site โ Helsinki,
- Ascendis Investigational Site โ Paris,
- Ascendis Investigational Site โ Berlin,
- Ascendis Investigational Site โ Cologne,
- Ascendis Investigational Site โ Dublin,
- Ascendis Investigational Site โ Milan,
- Ascendis Investigational Site โ Auckland,
- Ascendis Investigational Site โ Oslo,
- Ascendis Investigational Site โ Coimbra,
- Ascendis Investigational Site โ Stockholm,
- Ascendis Investigational Site โ London,
๐ Contact the Study Coordinator
Phone: (456) 124-2484
Email: asnd_registryinquiries@ascendispharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Achondroplasia
- A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH) โ Oakland, California
- An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia โ Oakland, California
- An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia โ Oakland, California
- Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH) โ Oakland, California
- A Study of TYRA-300 in Children With Achondroplasia: BEACH301 โ Torrance, California
- VIrtual STudy in Achondroplasia for the US (VISTA) โ Oakland, California
Explore by condition: All Achondroplasia clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.